Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM-PUL-001
- Development stage
- Unknown
- Lead developer
- VivaMed
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
VM-PUL-001 is an investigational monoclonal antibody being developed by VivaMed (also referred to as Vidamed) for the treatment of Acute Respiratory Distress Syndrome (ARDS). Currently in Phase 2 clinical development, the candidate is designed to address the severe inflammatory lung injury and respiratory failure associated with ARDS. Although the specific molecular target has not been publicly disclosed by the developer, the antibody-based approach suggests a targeted mechanism intended to modulate the immune or inflammatory response within the pulmonary environment to improve clinical outcomes in patients with acute respiratory failure.
Beyond the preview
Go deeper on VM-PUL-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM-PUL-001.